Document ID: chunk:federal_register_of_legislation:F2025L00049:schedule:4:p12
Version: federal_register_of_legislation:F2025L00049
Segment Type: schedule
Provision Reference: sch 4 (pt 12/22)
Character Range: 216793–220024

ENCEPHALITIS VACCINE.
KANAMYCIN.
KETANSERIN except in topical veterinary preparations containing 0.5% or less of ketanserin.
# KETAZOLAM.
KETOCONAZOLE except:
 (a) when included in Schedule 2; or
 (b) in preparations for dermal use containing 1% or less of ketoconazole for the treatment of the scalp; or
 (c) in preparations for dermal use for the treatment of tinea pedis.
KETOPROFEN except:
 (a) in preparations for dermal use; or
 (b) when included in Schedule 3.
KETOROLAC (includes ketorolac trometamol).
KETOTIFEN except when included in Schedule 2.
KHELLIN.
KITASAMYCIN except:
 (a) when included in Schedule 5; or
 (b) in animal feeds for growth promotion containing 100 mg/kg or less of antibiotic substances.
LABETALOL.
LACIDIPINE.
LACOSAMIDE.
LAMIVUDINE.
LAMOTRIGINE.
LANADELUMAB.
LANATOSIDES.
LANREOTIDE.
LANSOPRAZOLE except when included in Schedule 2 or 3.
LANTHANUM for therapeutic use.
LAPATINIB.
LARONIDASE.
LAROPIPRANT.
LAROTRECTINIB.
LATAMOXEF.
LATANOPROST.
LAUDEXIUM.
LAUROMACROGOLS in preparations for injection except:
 (a) when present as an excipient; or
 (b) when separately specified in these Schedules.
LEBRIKIZUMAB.
LECANEMAB.
LEDIPASVIR.
LEFETAMINE.
LEFLUNOMIDE.
LEMBOREXANT.
LENACAPAVIR.
# LENALIDOMIDE.
LENOGRASTIM.
LENVATINIB.
LEPIRUDIN.
LEPTAZOL.
LERCANIDIPINE.
LESINURAD.
LETERMOVIR.
LETROZOLE.
LEUPRORELIN.
LEVALLORPHAN.
LEVAMISOLE:
 (a) for human therapeutic use; or
 (b) in preparations for the prevention or treatment of heartworm in dogs.
LEVETIRACETAM.
LEVOBUNOLOL.
LEVOBUPIVACAINE.
LEVOCABASTINE except when included in Schedule 2.
LEVOCETIRIZINE except:
 (a) when included in Schedule 2; or
 (b) in divided preparations for oral use for the treatment of seasonal allergic rhinitis in adults and children 12 years of age and over when:

          (i) in a primary pack containing not more than 5 days' supply; and

          (ii) labelled with a recommended daily dose not exceeding 5 mg of levocetirizine.
LEVODOPA.
LEVOMEPROMAZINE.
LEVOMILNACIPRAN.
LEVONORGESTREL except when included in Schedule 3.
LEVOSIMENDAN.
LIDOCAINE except:
 (a) when included in Schedules 2 or 5; or
 (b) in dermal preparations containing 2% or less of total local anaesthetic substances per dosage unit; or
 (c) in lozenges containing 30 mg or less of total anaesthetic substances per dosage unit.
LIDOFLAZINE.
LIFITEGRAST.
LINACLOTIDE.
LINAGLIPTIN.
LINCOMYCIN.
LINDANE for human therapeutic use except when included in Schedule 2.
LINEZOLID.
LIOTHYRONINE.
LIPEGFILGRASTIM.
LIRAGLUTIDE.
LISINOPRIL.
LISURIDE.
LITHIUM for therapeutic use except:
 (a) when included in Schedule 2; or
 (b) when present as an excipient in preparations for dermal use containing 0.25% or less of lithium; or
 (c) in preparations containing 0.01% or less of lithium.
LIXISENATIDE.
LODOXAMIDE except when included in Schedule 2.
LOFEXIDINE.
LOGIPARIN for internal use.
LOMEFLOXACIN.
LOMUSTINE.
LOPERAMIDE except:
 (a) when included in Schedule 2; or
 (b) in divided oral preparations containing 2 mg or less of loperamide per dosage unit, in a primary pack containing 8 dosage units or less.
LOPINAVIR.
# LOPRAZOLAM.
LORACARBEF.
LORATADINE except:
 (a) when included in Schedule 2; or
 (b) in divided preparations for oral use for the